Marta Lipowska

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Myasthenia gravis: the changing treatment landscape in the era of molecular therapies

Determinants of Quality of Life in Myasthenia Gravis Patients

Antititin antibody in early- and late-onset myasthenia gravis